CD86 and myeloid sarcoma: Comparing CD14+ and CD16+ monocytes in detail, both CD14+ and CD16+ monocytes expressed activation markers (CD86, CD40) and anti-inflammatory cytokines (IL10) which were upregulated in the CSF of MS patients (Fig. 4G).